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ABSTRACT 
 
 
 
 Although mutations in BRCA1 and 2 genes have previously been linked to breast 
cancer, mutations in genes encoding other proteins in the BRCA DNA repair pathway 
could also lead to this disease.  This MQP used a candidate gene screening approach to 
identify potential genetic changes in proteins previously shown to interact with BRCA1 
and/or BRCA2 in repair pathways.  PCR amplicons were analyzed by high resolution 
melting analysis (HRMA) as a preliminary screen for mutations in six candidate genes 
(Mre11, Rad50, MCPH1, NBS1, DSS1, and BCCIP) amplified from non-
BRCA1/BRCA2 breast cancer patient samples from BRCA-independent high-risk 
families.  Mutations in MCPH1 were further analyzed by DNA sequencing, which 
showed frameshift/nonsense mutations, missense mutations, silent substitutions, and 
intronic variants in 29 patients, 10 of which contained more than one mutation.  
Mutations in exon-2 of DSS1 include protein truncating and missense mutations in highly 
conserved domains.    
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BACKGROUND 
 
Breast Cancer Description 
Breast cancer is a malignancy that develops in tissues of the breast, usually in the 
ducts and lobules.  It occurs in a greater percentage in females, and rarely in males 
(National Cancer Institute, 2007).  Some of the first physically identifiable symptoms of 
breast cancer include a lump or swelling, skin dimpling, nipple pain, discharge, or 
retraction, redness, or scaliness of the nipple or breast skin (American Association for 
Cancer Research, 2007).   
Mammography is an effective and widely used diagnostic tool to detect changes 
in breast tissue that may indicate cancer. Other diagnostic methods used are digital 
mammography, magnetic resonance imaging, positron emission tomography, Sestamibi 
scintimammography, and ductal lavage (National Cancer Institute, 2007).  Family history 
of breast cancer is the greatest predictor of risk for developing the disease.  Other factors 
include age, previous history of breast cancer, history of chest radiation therapy before 
age 30, and existence of having dense breast tissue, particularly in older individuals. 
Women with a history of early onset of menses or late age menopause, women who have 
never had children or who have children after age 30, women who are obese after 
menopause, or who use menopausal hormone therapy with estrogen plus progestin are 
also considered to have increased risk for breast cancer (American Association for 
Cancer Research, 2007; National Cancer Institute, 2007).   
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Breast Cancer Prevalence 
 Breast cancer is the second leading cause of cancer deaths in American women 
(Friedenson, 2005).   In 1997, breast cancer claimed the lives of approximately 44,910 
Americans, with 43,900 women and 290 men losing their lives to the disease. 
Approximately two million women living in the U.S. have been diagnosed with breast 
cancer.  The National Cancer Institute (2007) predicts that in the United States in 2007, 
there will be 178,480 newly diagnosed cases of breast cancer in females, and 2,030 new 
cases in males. Over 40, 000 people will die from breast cancer in 2007 (40,460 females 
and 450 males) (National Cancer Institute, 2007). Mortality rates have, however, 
decreased an estimated two percent per year in the past decade, with greater decreases 
seen among young women (American Association for Cancer Research, 2007), possibly 
due to mammography screening, early diagnosis, and  improved management (adjuvant 
tamoxifen therapy) and treatment of women with breast cancer (Hermon and Beral, 
1996). 
 
Risk Reduction Options in Familial Breast Cancer 
Familial breast cancer is characterized by early onset diagnosis, an increased risk 
of bilateral breast cancer, an increasing risk with increasing numbers of affected family 
members, and increased risk for ovarian cancer. Women who have BRCA1 and BRCA2 
gene mutations face this increased risk for breast and ovarian cancer.  BRCA1 and 
BRCA2 account for almost 80% of hereditary breast cancer, and 5 to 6% of all breast 
cancers (Greene, 1997).  At least eight candidate breast cancer susceptibility genes have 
currently been identified (Greene, 1997) (discussed later). In a study conducted by the 
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Breast Cancer Linkage Consortium, 52% of families with breast cancer demonstrated 
linkage to BRCA1, while 32% were linked to BRCA2, suggesting that 16% of breast 
cancer families were linked to other predisposing genes (Ford et al., 1998). BRCA1 was 
linked to 81% of breast-ovarian cancer families, while 14% were linked to BRCA2. 
Linkage to BRCA2 was identified in76% of families with male and female breast cancer 
(Ford et al., 1998).  The cumulative risk of breast cancer was 27% by age 50 years, which 
increased to 84% by age 70 years. Ovarian cancer risks were much smaller, at 0.4% until 
age 50 years, but rose to 27% by age 70 years (Ford et al., 1998).   
 Some risk-reduction options are made available, as part of genetic counseling for 
women who are BRCA1 or BRCA2 mutation carriers. Options offered include increased 
surveillance, chemoprevention with tamoxifen, prophylactic oophorectomy (removal of 
the ovaries), and prophylactic mastectomy (Uyei et al., 2006). 
          Uyei et al. (2006) reported a retrospective analysis of 554 women with BRCA1 and 
BRCA2 gene mutations who were treated at The University of Texas M. D. Anderson 
Cancer Center.  Results obtained for data collected between 2000 and 2006 demonstrated 
that women who had BRCA mutations, along with a history of breast cancer or ductal 
carcinoma in situ, or a history of having had previous breast biopsies, were more likely to 
select prophylactic surgery. Women with a family history of ovarian cancer opted for 
prophylactic oophorectomy, while an individual’s personal history of ovarian cancer or 
advanced breast cancer was more likely associated with a choice for surveillance only. 
Breast cancer survivors with a history of treatment with total mastectomy chose 
prophylactic mastectomy more often than breast cancer survivors with a history of 
treatment with breast-conserving surgery or women with no history of breast cancer 
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(Uyei et al., 2006).  Hartmann et al. (2001) reported that bilateral prophylactic 
mastectomy decreased the risk of breast cancer in women with BRCA1 and BRCA2 
mutations by approximately 90%.  
Researchers at Lombardi Comprehensive Cancer Center in Washington, DC 
reported that BRCA1 and BRCA2 carriers are recommended to undergo prophylactic 
bilateral salpingo-oophorectomy (removal of an ovary with a fallopian tube) by age 35-40 
years or when childbearing is complete, in an effort to significantly reduce the risk of 
ovarian cancer (Nusbaum and Isaacs, 2007). This prophylactic surgery has been shown to 
also reduce the risk of breast cancer when performed in premenopausal mutation carriers. 
Finch et al. (2006) studied the incidence of ovarian, fallopian tube, and primary 
peritoneal cancer in a large cohort of women with BRCA1 or BRCA2 mutations. 
Prophylactic oophorectomy
 
reduced the risk of ovarian
 
and fallopian tube cancer in the 
BRCA1 and BRCA2 carriers by approximately 80%, although there was a post-
oophorectomy residual risk of approximately 4% to develop peritoneal cancer (Finch et 
al. 2006).  BRCA1 and BRCA2 carriers are also offered the option of increased 
surveillance, with or without chemoprevention, or prophylactic surgery as part of a breast 
cancer management protocol.  Bilateral prophylactic oophorectomy is more commonly 
chosen than bilateral prophylactic mastectomy in BRCA1/2 mutation carriers who are 
unaffected (Freibel et al., 2007), as many women feel that bilateral prophylactic 
mastectomy is too aggressive with increase risk for side effects (Uyei et al., 2006).   
BRCA carrier status, to date, is not used as an independent factor to determine 
prognosis for systemic treatment options (Nusbaum and Isaacs, 2007). Recently, 
researchers have investigated the use PARP-1 [poly(ADP-ribose) polymerase-1] 
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inhibitors as a chemotherapeutic treatment for BRCA1/2 cancers. DeSoto and Deng 
(2006) suggested that BRCA breast cancer cells were resistant to PARP-1 inhibitors 
when used alone in the treatment. PARP-1 inhibitors did offer promise in the prevention 
of BRCA related breast cancers, and may be successful when used in combination with 
other chemotherapeutic agents in the treatment of BRCA related breast cancer (DeSoto 
and Deng, 2006). 
  
Genetic Causes of Breast Cancer 
BRCA1 and BRCA2  
Approximately 5-10% of all breast cancer results from the inheritance of highly 
penetrant mutations in two susceptibility genes, BRCA1 (OMIM, 113705; GenBank, 
U14680.1; Hall et al., 1990) and BRCA2 (OMIM, 600185; GenBank, U43746.1; 
Wooster et al., 1994) which is consistent with an autosomal dominant transmission (Ford 
et al., 1998; Pohlreich et al., 2005).  These genes were first identified in 1994 (Miki et al., 
1994; Wooster et al., 1994; Breast and Ovarian Cancer, 2007), and are associated with 
both breast and ovarian cancers (Troudi et al., 2007).  Mutations in these two genes 
account for 60% of all known mutation site-specific female breast cancers (Ford et al., 
1998).   BRCA1 is found on the long arm of chromosome 17, mapped specifically to 
chromosome 17q21 (Hall et al., 1990).  The BRCA1 gene contains 24 exons, and 
encodes a protein of approximately 220 kDa (1863 amino acids) (Cipollini et al., 2004). 
     BRCA2 is located on the long arm of chromosome 13. BRCA2 is also a large gene, 
containing 27 exons that encode a protein of 380 kDa (3418 amino acids).  Both BRCA1 
and BRCA2 have an unusually large exon 11. The translational start site for both genes is 
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in exon 2.  Both proteins are predominately nuclear, where phosphorylated versions of 
both proteins are also located (Cipollini et al., 2004).   While similar in some respects, 
many differences exist between the two genes, which are not homologous. BRCA1 has 
two protein motifs, while BRCA2 has BRC repeats and no relation to BRCA1 (Cipollini 
et al., 2004) and is not highly conserved evolutionarily (Szabo et al., 1996). 
BRCA1 and BRCA2 function as tumor suppressors, and are critical to the cellular 
control of homologous recombination and double-strand break repair when DNAs are 
damaged (Liu and West, 2002; Ford et al., 1994; Friedenson, 2005). Individuals with 
mutations in these genes possess an increased lifetime risk for developing breast or 
ovarian cancer.  The cumulative risk of for developing breast cancer is approximately 
28% by age 50 years, and 84% by age 70 years, with ovarian cancer risks determined to 
be  0.4% by age 50 years and 27% by age 70 years (Ford et al., 1994). The lifetime risk 
for developing breast cancer is similar in both BRCA1 and BRCA2 carriers, with a 
possible lower risk in BRCA2 carriers <50 years of age (Ford et al., 1994).  
Both BRCA1 and BRCA2, when functioning normally, play an active role in the 
restoration of double-stranded breaks in DNA caused by radiation, which can occur 
through exposure to DNA damaging agents(ionizing radiation) or through errors in 
normal cellular replication (such as DNA synthesis, chromosomal segregation, metabolic 
generation of oxygen radicals).  Inactivating mutations occurring in BRCA1 or BRCA2 
hinder the repair of DNA damage through homologous recombination. The accumulation 
of mutations due to impaired DNA repair promotes the growth of cancer (Breast and 
ovarian cancer, 2007).  Researchers have reported that BRCA1 mutations also confer 
modest risks for uterine, cervical, early-onset prostate and pancreatic cancers. BRCA2 
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mutations show a similar increased risk for prostatic, pancreatic, gallbladder, bile duct, 
stomach cancers and melanoma (Easton et al., 1995; Friedenson, 2005). 
Approximately 2000 distinct sequence variants in BRCA1 and BRCA2 have 
already been recorded (Breast Cancer Mutation Database, 2007).  Both BRCA1 and 
BRCA2 genes have variants that are uniformly distributed along the entire coding 
regions. Mutations have also been identified in intronic sequences flanking each exon in 
both genes, some of which lead to altered splicing.   
Breast cancer develops in a multistep process and is influenced by two types of 
genes, oncogenes and suppressor genes (Osborne et al., 2004).  Oncogenes refer to genes 
that, when activated, can contribute to
 
the development of cancer.  Oncogenes produce 
alterations that cause gain-of-function effects (Osborne et al., 2004).  Tumor suppressor 
genes function in slowing down cell growth, DNA repair, and apoptosis (American 
Cancer Society, 2005). These genes refer to group of genes whose loss of function
 
promotes malignancy. Germline mutations in breast cancer occur in tumor suppressor 
genes. Tumor suppressor genes can also contain sporadic acquired somatic mutations. 
The tumor typically contains a mutation in one allele
 
and a deletion of the remaining 
allele. In 1971, Alfred Knudson proposed this "two-hit" hypothesis (in reference to 
retinoblastoma) which stated that both gene alleles must
 
be missing to unmask the 
malignant phenotype. The activation of an oncogene and the mutation of a tumor 
suppressor
 
gene can produce changes that contribute to the
 
malignancy. The effects of 
these alterations are complex
 
due to the high number of changes in a typical case of 
breast
 
cancer and the interactions of the biological pathways involved (Osborne et al., 
2004). 
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Cancer risks increase from missing BRCA1 or BRCA2 protein sequences or non-
functional proteins, most likely caused by frameshift, nonsense, and splice site mutations 
(Cipollini et al. 2004).  Figure 1 shows how BRCA1and BRCA2 act as tumor suppressor 
genes (deduced from an analysis of tumor specimen DNAs) (copied from Cipollini et al. 
2004).  An initial mutation in one allele (white circle in the figure) leads to a diminished 
capacity for DNA repair.  Eventually, the second non-mutated allele is entirely deleted 
(figure right side). 
 
 
 
Figure 1.  Proposed Mechanism for Loss of Allele Function for BRCA1 and BRCA2 Tumor 
Suppressor Genes.  Initially one allele suffers a germline susceptibility point mutation or small deletion 
(white circle), which leads to a diminished capacity for repairing DNA.  Eventually the second unmutated 
allele is deleted entirely, as found in tumor specimens (Copied from Cipollini et al. 2004). 
    
   
The Role of Founder Mutations 
The proportional contribution of BRCA1 and BRCA2 mutations has been shown 
to differ in different populations around the world (Szabo and King, 1997).  Vogel et al. 
(2007) described eight different BRCA mutations and three variants within a small 
sample in a Hispanic population.  One of three mutations in the BRCA1 and BRCA2 
genes was found in 2.0%-2.5% of Ashkenazi Jewish women (Struewing et al., 1997). 
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Studies have suggested that each founding mutation put these women at a high risk of 
invasive breast cancer, which continues throughout life (Struewing et al., 1997; Warner 
et al., 1999).  In addition, an estimated 12% of the total number of breast cancers in the 
Ashkenazi Jewish population is caused by mutations in the BRCA1 or BRCA2 gene 
(Warner et al., 1999).  Peto et al. (1999) reported that the mutation BRCA1-185delAG 
has been identified in 20% of Ashkenazi Jewish women with early onset breast cancer, 
while the mutation BRCA2- 6174delT is found in 8% of the Ashkenazi cases diagnosed 
in women over 42 years of age. The authors speculated that, among Ashkenazi Jews, 
BRCA1 mutations play a significant role in the risk for early-onset breast cancer, while 
BRCA2 mutations affect the later onset of the disease.  Ganguly et al. (1997) found that 
that lower prevalence of mutations in both BRCA1 and BRCA2 genes was observed from 
data collected from clinical families. Higher prevalence was found in linkage data 
obtained from high-risk families collected in a research setting (Ganguly et al. 1997).  
 In Britain, BRCA1 mutation carriers were found in 3.1% of breast cancer 
patients, and BRCA2 mutations in 3.0% of breast cancer patients under the age of 50 
(Peto et al., 1999).  For patients 50 years of age or older, the prevalence was 0.49% and 
0.84%, respectively.  Similarly, researchers in Australia found that an estimated 3.8% of 
women before age 40 in that country carried a germline mutation in BRCA1 (Southey et 
al., 1999). They reported seven rare BRCA variants, but argued that these did not have a 
significant effect on the risk of breast cancer in the population studied.   
In a recent study of 204 breast cancer patients in northern India, researchers found 
a lower proportion of BRCA1 and BRCA2 mutations than seen in other populations, 
although the proportion was still elevated for breast cancer patients versus the general 
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population (Saxena et al., 2006).  Interestingly, 9 distinct BRCA1 and 9 distinct BRCA2 
sequence variants were identified.   4 of the 9 BRCA1 mutations were unique to the 
Indian population, accounting for 44% of the BRCA1 mutations found.  Of the 9 BRCA2 
mutations, 7 mutations (78%) were unique to the Indian population, accounting for 78% 
of the BRCA2 mutations.  In this group of patients studied from Northern India, these 
unique mutations were distributed throughout the BRCA1 and BRCA2 gene exons 
(Saxena et al., 2006). 
Szabo and King (1997) analyzed the results of previous studies conducted by 
researchers in seventeen countries, including Italy, Finland, Norway, Iceland, Israel, 
Russia, Japan, Canada, Britain, and the United States.  They explained that great 
variability was noted among populations for proportions of high-risk families with 
BRCA1 mutations.  Russia displayed the largest proportion of BRCA1 mutations, 
occurring in 79% of families with breast or ovarian cancer.  Affected families had one of 
two common alleles. The most common allele in Russia was BRCA1-5382insC, which is 
also the most common allele found among the Europeans studied.  The second most 
common allele in Russia was BRCA1-4153delA (Szabo and King, 1997). This allele has 
also been identified in affected families in Latvia (Csokay et al., 1999), Poland (Gorski et 
al., 2000; Gorski et al., 2004), and Lithuania (Gronwald et al., 2005).  Israel 
demonstrated the next highest proportion of BRCA1 mutations in inherited breast and 
ovarian cancer, occurring in 47% of high-risk families (Szabo and King, 1997).  BRCA1 
mutations were observed in 29% of Italian high-risk families, and in 20-25% of high-risk 
families in Britain, France, Scandinavia, and Hungary.  Less than 20% of high-risk 
families in Holland, Belgium, Germany, Norway, and Japan had BRCA1 mutations.  
 15 
Significantly fewer cases of BRCA2 mutations were noted for all countries except 
Iceland, where a single BRCA2 mutation, specifically the 999del5 mutation, was 
responsible for all the inherited breast and ovarian cancer in that country.   
BRCA2 mutations are also more common than BRCA1 mutations in familial 
male breast cancer, occurring in about 19% of familial male breast cancer in the United 
States (Szabo and King, 1999).   Overall, the authors proposed that “BRCA1 and BRCA2 
have each undergone multiple mutations; the resultant alleles have migrated with the 
peoples in which they occur; and disease-associated mutations have persisted, no doubt 
because of late onset of disease and, hence, little or no deleterious impact of mutant 
alleles on genetic fitness” (Szabo and King, 1997). 
 
 Non-BRCA Genes Associated with Breast Cancer 
 Recent studies suggest that the proportion of familial breast
 
cancer cases due to 
the BRCA1 and BRCA2 mutations may
 
be smaller than initially believed (Kainu, et al., 
2000).  Mutations in BRCA1 and BRCA2 account for only about 60% of mutation site-
specific female breast cancers (Ford et al., 1998), so additional susceptibility genes likely 
exist (Walsh and King, 2007).  But to date, gene identification efforts using linkage 
analysis have not been successful at identifying non-BRCA genes, likely because that 
approach identifies individual genes, each of which confers only a moderate risk 
(Antoniou and Easton, 2006).   
Kainu et al. (2000) used mathematical models to look for early somatic genetic 
deletions
 
in tumor tissues, and then applied targeted linkage analysis. The authors used 
comparative
 
genomic hybridization to investigate 61 breast tumors from
 
37 breast cancer 
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families, none of whom had BRCA1 or BRCA2 mutations.
  
Mathematical models 
predicted a loss of chromosome arm 13q as one of the first genetic events in these 
familial cancers. This was demonstrated in a study of a Swedish family with five breast 
cancer cases, where all patients evidenced clear 13q deletions at 13q21-q22 (Kainu, et al., 
2000).  A subsequent study by Thompson et al., (2002) found no linkage to a 
susceptibility locus at chromosome 13q21 and concluded that, if it did exist, its 
contribution would be minimal in breast cancer families of European origin.  
There exist multiple biologic functions for BRCA1 and BRCA2 proteins, 
including “participating within a pathway that mediates error-free repair of DNA double 
stranded breaks by homologous recombination (Friedenson, 2005).”  BRCA1 and 
BRCA2 gene products are placed within a biochemical sequence, which includes the 
MRE11, Rad50 and NBS1 complex (MRN complex), ATM, CHEK2, BRCA1, BRCA2, 
and Fanconi anemia proteins, often referred to as the BRCA pathway (Figure-2, 
Friedenson, 2007).  A breakdown in the critical protein function anywhere within this 
DNA repair BRCA pathway may introduce mutations by repair of double strand breaks 
by lower fidelity, error prone methods.  Because some cancers are mediated by these 
errors, this results in an increased risk for development of those cancers (Friedenson, 
2005).  More recently, Friedenson (2007) proposed that inactivation of any component 
within the BRCA pathway would increase the risks for not only breast and ovarian 
cancers, but also for lymphomas and leukemias. Where BRCA pathway mutations do not 
exist, the functional encoded proteins provide protection from both breast and ovarian 
cancer.   
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Figure 2. Schematic Diagram of the 
BRCA Pathway for DNA Repair.  Note 
that BRCA1 and BRCA2 are only a part of 
this key DNA repair pathway, which if any 
key protein is rendered non-functional by 
mutation, DNA mutations subsequently 
increase. Thus this model predicts non-
BRCA mutations should also correlate 
with breast cancer.   (Figure from 
Friedenson, 2007) 
 
 
 
 
Gene mutations cause inactivation of BRCA1, BRCA2, and other critical proteins 
within this "BRCA pathway" that inactivate this error-free repair process (Friedenson 
2007).  Liu and West (2002) described the pathway, which illustrates how, even though 
BRCA1 and BRCA2 proteins interact together, only a minority of the BRCA1 protein is 
actually found in association with BRCA2 at a given time.  Recent identification of more 
proteins that associate with either BRCA1 or BRCA2 further emphasizes that BRCA1 
and BRCA2 each participate in different protein complexes, and these each have distinct 
functions in DNA double strand breakage repair (See Figure 3 and Table I below). 
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Figure 3.  Interactions of BRCA1 and BRCA2 With Other Proteins, or Protein Complexes. These 
proteins were identified by two-hybrid screens, co-immunoprecipitation analyses, and co-fractionation 
studies.  In general, the protein–protein associations of BRCA1 have been shown to be distinct from those 
exhibited by BRCA2.  (Copied from Liu and West, 2002)   
 
 
 
 
 19 
Biological Functions BRCA-1-Interacting Proteins 
DDR and repair MSH2, MSH6, MLH1, ATM, BLM and the RAD50-
MRE11-NBS1, DNA replication factor C, RAD51, 
Fanconi anemia proteins, PCNA, H2AX, c-Abl, MDC1 
Tumor suppressors ATM, ATR, p53, BRCA2, RB, BARD1, BACH1 
Oncogenes c-Myc, casein kinase II, E2F1, E2F4, STK15, AKT 
Transcription RNA polymerase II holoenzyme (RNA helicase A, 
RPB2, RPB10α), CBP/p300, HDC and CtIP, estrogen 
receptor α, androgen receptor, ZBRK1, ATF1, STAT1, 
Smad3, BRCT-repeat inhibitor of hTERT expression 
(BRIT1) 
Cell cycle related Ayclin A, Cyclin D1, Cyclin D1, CDC2, Cdk2, Ckd4, 
γ-tublin, p21, p27 
Stress response, apoptosis MEKK3, IFI16, X-linked inhibitor of apoptosis protein 
(XIAP) 
Others BAP1, BIP1, BRAP2, importin α 
 
Table 1.  A list of BRCA1 Interacting Proteins.  (Copied from Deng, 2006). 
     
CHEK2 (OMIM 604373) (shown as purple in Figure-2, but not shown in Figure-3 
or in Table-I) is a key checkpoint kinase of the BRCA pathway that serves as a tumor 
suppressor in response to DNA double-strand breakage.  The CHEK2*1100delC 
mutation most likely accounts for familial risk of breast cancer in some non-BRCA1 and 
non-BRCA2 patients, causing DNA damage and activation of cell-cycle checkpoints that 
block cell proliferation and DNA repair.  The impaired function of these checkpoints 
results in instability in the genome and a subsequent increased risk for cancer (Weischer 
et al., 2007).  Investigators in Denmark reported the results of a 34 yearlong study of a 
large sample in the Danish population (Weischer et al., 2007).  The authors concluded 
that CHEK2*1100delC heterozygosity was associated with a three-fold risk of breast 
cancer in the Danish women studied.  Conversely, researchers investigating a small 
sample of hereditary breast and ovarian cancer families from the Slovak Republic did not 
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detect any 1100delC variant of the CHEK2 gene (Cierniková et al., 2005).  Instead, the 
investigators found a spectrum of eight mutations, one novel BRCA1 deletion, and one 
recurrent BRCA2 mutation. 
Other candidate genes have been found to act directly in double strand DNA 
break repair.  Walsh, et al. (2006) studied 300 US families with 4 or more cases of breast 
or ovarian cancer who tested negative (wild type) for BRCA1 and BRCA2 mutations. 
Patients were screened for genomic rearrangements in BRCA1 and BRCA2, and 
germline mutations in CHEK2, TP53, and PTEN.  Based on their findings, these 
researchers estimated that, in a similar cancer population, one might expect that 
approximately 12% would demonstrate a large genomic deletion or duplication in either 
BRCA1 or BRCA2, and that 5% would carry a mutation in CHEK2 or TP53.  Recently, 
several mutations in genes in the BRCA-related pathways (Chek2, ATM, PALB2, 
BRIP1) were shown to be associated with familial breast cancer (Walsh and King, 2007).   
Besides BRCA1 and BRCA 2, other genetic syndromes are associated with 
autosomal dominant inheritance of breast cancer risk. These include Li–Fraumeni 
syndrome (a genetic disorder that causes breast cancer), as well as bone cancer 
(osteosarcoma), muscle and soft tissue cancers, brain tumors, leukemias, and cancer of 
the adrenal glands.  These are caused by germline mutations in another key tumor 
suppressor gene, p53, found in over 50% of families, with a reported penetrance of at 
least 50% by age 50 years.  Germline mutations in hCHK2 and TP53 genes have also 
been associated with the Li-Fraumeni syndrome and related breast cancer (Cipollini et al., 
2004; Li-Fraumeni Syndrome, 2007).  Cowden syndrome is caused by PTEN germline 
mutations that promote an increased risk for not only developing breast cancer, but also 
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thyroid and endometrial cancer (lining of the uterus).  In addition, patients with Cowden 
syndrome are at risk for developing noncancerous breast and thyroid diseases, as well as 
growths on the skin and mucous membranes called hamartomas (Cipollini et al., 2004; 
Cowden Syndrome, 2007). 
Approximately 1% of the general population may be heterozygote carriers of an 
ATM gene mutation responsible for ataxia telangiectasia, a genetic autosomal recessive 
disorder, with known risks for developing breast cancer (Cipollini et al., 2004). Another 
identified autosomal recessive disorder, Peutz–Jeghers syndrome is characterized by 
early onset of symptoms, which include hamartomatous polyps in the gastrointestinal 
tract (Peutz-Jeghers Syndrome, 2007).  Patients with Peutz–Jeghers syndrome face 
lifetime risks for cancers of the gastrointestinal tract, pancreas, cervix, breast, and ovaries 
(Cipollini et al., 2004; Peutz–Jeghers syndrome, 2007).  Approximately half of the 
patients with Peutz–Jeghers syndrome have mutations in STK11, which place them at 
very high risk of developing breast cancer (Cipollini et al., 2004).  
 A recent study in Montreal found a high penetrance of PALB2 mutations in 
probands (initial subjects tested) tested in 68 BRCA1/BRCA2-negative breast cancer 
families of Ashkenazi Jewish, French Canadian, or mixed ethnic descent (Tischkowitz et 
al., 2007).  Seal et al. (2006) looked at truncating mutations in the Fanconi anemia J gene 
BRIP1 in BRCA1/BRCA2 mutation-negative families. The authors reported that these 
BRIP1 mutations could pose a risk as low-penetrance breast cancer susceptibility alleles. 
However, other investigators were unable to substantiate an increase in risk of familial 
breast cancer from BRIP1 variants (Lewis et al., 2005; Frank et al., 2007).  Researchers 
in Finland analyzed the Mre11 complex, composed of RAD50, NBS1 and MRE11 and 
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found that RAD50 and NBS1 haplo-insufficiency affected genomic integrity and 
increased susceptibility to breast cancer (Heikkinen et al., 2006).  The MRN complex is 
comprised of MRE11, RAD50, and NBS1, which is the product of Nijmegan breakage 
symdrome (Robert et al., 2006). Persons with Nijmegan breakage syndrome (NBS) are 
susceptible to immunodeficiency and increased risk of malignancies (Tauchi et al., 2002). 
The NBS1 gene product, nibrin, along with the rest of the MRN complex, is responsible 
for detecting, signaling and repairing double strand breaks in DNA, and acts as a sensor 
to recruit ATM to repair broken DNA molecules (Robert et al., 2006).   
Li et al. (2006) recently investigated the protein DSS1 and described it as an 
evolutionarily conserved acidic protein that binds to BRCA2.  The authors explained that 
DSS1 depletion causes hypersensitivity to DNA damage, similar to that seen with 
BRCA2. They found that the presence of DSS1 was essential to the stability of the 
BRCA2 protein in mammalian cells. Deletion, suppression, or mutation of DSS1 is 
speculated to promote human breast and ovarian cancer, as well as sporadic and familiar 
breast cancer where BRCA1 and BRCA2 mutations are not present (Li et al. 2006).   Lu 
et al. (2007) recently reported the results of their study, which showed that BCCIP 
regulates homologous recombination and suppresses spontaneous DNA damage. They 
proposed that BCCIP fragments that interact with BRCA2, or with the protein interacting 
p21, inhibit DNA double-stranded break repair through homologous recombination. 
When breaks in DNA structure occur, responses at the cellular level set off 
numerous checkpoint and repair proteins. These responses synchronize a complex 
signaling cascade that detects the DNA damage, with subsequent checkpoint activation, 
DNA repair, cell cycle arrest and/or apoptosis (Chaplet et al. 2006).  Lin et al. (2005) 
 23 
studied the function of BRIT1 in DNA damage checkpoints. BRIT1 is identical to the 
MCPH1 gene. Mutations in this gene are also found in patients with primary 
microcephaly. BRIT1 is required for the expression of both BRCA1 and the checkpoint 
kinase. Chk1 and phosphorylation of Nbs1 are dependant on BRIT1/MCPH1. The 
authors speculated that since BRIT1/MCPH1 regulates Nbs1, BRCA1, and Chk1, defects 
in BRIT1 will likely cause checkpoint defects.  Rai et al. (2006) proposed that BRIT1 
levels contribute to tumor progression by increasing the instability of the gene and 
promoting metastasis. The authors emphasized that previous studies had shown that 
BRIT1 expression was inversely correlated with the likelihood of breast cancer 
metastasis and with the duration of relapse-free survival. The authors found decreases in 
BRIT1 in the breast and ovarian cancer specimens studied. 
     The action of BRIT1 in signaling DNA damage is organized in a hierarchical 
fashion as seen in Figure 4.  The model proposed by Chaplet et al. (2006) suggests that 
BRIT1 involvement begins early in the recruitment, and subsequent triggering of DNA 
damage induces early mediators in the repair pathway. 
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Figure 4.   A Model of BRIT1 Functions in DNA Damage Response, Genomic Integrity, and Tumor 
Suppression.  BRIT1 is an early regulator of the DNA damage response in both ATM and ATR pathways, 
and is required for the expression of BRCA1 and Chk1. BRIT1 also functions as an adaptor downstream of 
Chk1 in the ATR pathway, and is essential for maintenance of genomic integrity and tumor suppression.” 
(Copied from Chaplet et al., 2006) 
 
Chaplet et al. (2006) contend that BRIT1 may also be necessary to preserve an 
intact chromatin structure, which is also essential to the DNA damage checkpoint and 
repair machinery. BRIT1 depletion eliminates the DNA damage checkpoint and repair 
response, causing both centrosomal defects as well as chromosomal aberrations. Human 
carcinomas have been shown to have aberrantly reduced expression of BRIT, suggesting 
that BRIT1 plays a role in the development and progression of cancer, further supporting 
the role of BRIT1 as a tumor suppressor (Chaplet et al., 2006). 
Although biochemical analyses have shown that multiple proteins participate in 
the BRCA pathway for the repair of double stranded DNA breaks, and a loss of their 
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function should hypothetically correlate with an increased risk of breast or ovarian 
cancer, to date, gene identification efforts using linkage analysis have not been successful 
at identifying non-BRCA genes. This is likely because that approach identifies individual 
genes, each of which confers only a moderate risk (Antoniou and Easton, 2006).  Perhaps 
a direct candidate gene sequencing effort which targets known BRCA pathway-
associated genes will succeed. 
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PROJECT PURPOSE 
 
 The overall objective of this project was to identify mutations within novel BRCA 
pathway-associated genes that might contribute to the onset of breast cancer.  The lab’s 
main hypothesis is that the genetic loss of any gene related to DNA repair, and in 
particular those genes known to participate in the BRCA-associated DNA repair pathway, 
can lead to a loss of DNA repair, and the formation of cancer.  This MQP study used a 
candidate gene screening approach to identify novel susceptibility genes by directly 
sequencing the coding regions of genes previously shown to interact with BRCA1 and/or 
BRCA2 in the BRCA DNA repair pathway (Liu and West, 2002).  PCR amplicons for 
genes Mre11, Rad50, NBS1, DSS1, BCCIP, and MCPH1 were amplified from patient 
DNAs from high-risk non-BRCA1/BRCA2 families.  The amplicons were then analyzed 
by High Resolution Melting Analysis (HRMA) to identify potential variants.  Variants 
for MCPH1 were further analyzed by DNA sequencing.  
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METHODS 
 
Tissue Source 
     Germline DNA samples from blood were obtained from 288 subjects with a history of 
breast cancer.  All subjects were patients from high-risk non-BRCA1/BRCA2 families, 
obtained from various collaborating centers in Europe and the United States.   
 
DNA For PCR Optimization 
 Human placental DNA (Clontech) was used for PCR optimization. 
 
PCR 
 Mutation analysis was performed on specific candidate genes known to 
participate in the BRCA pathway for DNA repair using traditional PCR (not real time 
PCR) followed by DNA sequencing.   
 
PCR Primer Pair Optimizations  
PCR primer pairs were designed using bioinformatics tools for specific gene 
exons for the following genes:  MCPH1, NBS1, DSS1, and BCCIP.  Bioinformatics tools 
included online applications such as Primer3 Input v. 0.4.0., UCSC’s ePCR and BLAT, 
and NCBI’s GenBank.  NCBI’s GenBank was accessed in order to obtain cDNA 
information for the novel susceptibility genes.   
Primer-3 was used to pick the primer pairs, which were then analyzed to confirm 
that each forward primer melting temperature was similar to the reverse primer melting 
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temperature, resulting in a more stringent annealing temperature range for the PCR 
product.  By analyzing the Primer3 output, primer conditions could be created to avoid 
primer dimer formation and check for stem-loop structures.  The primer pairs were also 
designed to include a length of approximately 50 nucleotides on either end of the exon to 
ensure that the entire coding region would be included.  These conditions were necessary 
for designing primer pairs for mutation screening of all coding sequences and intron and 
exon boundaries.  PCR product size was limited to less than 500 bp for optimal HRMA 
sensitivity. For large exons, overlapping PCR products were amplified to fit these 
conditions.  UCSC’s ePCR and BLAT applications determined each primer pair derived 
from unique sequence within the human genome to produce a single PCR product.  
 The new primers were obtained from Integrated DNA Technologies.  
Optimization of PCR conditions was performed using human placental DNA provided by 
Clontech for each primer pair, and also for existing primer pairs for MRE11 and RAD50.  
Optimization was defined as the specific conditions producing the maximum amplicon 
band intensity without non-specific band amplification.  Ideal PCR conditions were 
determined using a gradient cycler sampling 10 Tm (annealing temperatures) per primer 
pair.  Each reaction contained 20 ng of human placental DNA, PCR master mix (1X 
Buffer, 1mM MgCl2, 200 μM dNTPs, 0.5 U Qiagen Hotstar Taq Polymerase), and 
individual primer pairs (250 uM each) in 96-well Bio-Rad polypropylene Multiplate 
format.  The PCR machine used was a Peltier Thermal Cycler DNAEngine Tetrad2 
created by MJ Research.  PCR amplification used the general protocol, shown in Table-
II, and any change from the general protocol is given in the figure legends.   
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Table-II:  General PCR Conditions Used for Gene Amplification 
Step Temperature Time Purpose 
1 95ºC 15 Min Initial denaturation and activation of enzyme 
2 95ºC 30 Sec Denaturation 
3 50-72ºC 30 Sec Temperature gradient annealing 
4 72ºC 30 Sec Amplification 
5  2 Hrs Repeat steps 2-4, 39 more times 
6 72ºC 5 Min Elongation 
7 25ºC ∞ Incubation 
  
 
PCR of Candidate Genes 
Optimized PCR conditions for each gene were then implemented on germline 
DNA from patient blood samples.  PCR was performed on white 384-well Bio-Rad 
Microseal Polypropylene Microplates, each reaction containing 10 ng of non-BRCA1/2 
high risk patient DNA.  High-throughput liquid handling robotics were used for sample 
transfer (BIOMEK). White PCR plates were necessary for fluorescence analysis to 
prevent fluorescence bleed from well to well.  The brand of PCR machines used for PCR 
of the candidate genes included Hybaid Satellite 384 Thermal Cyclers and Thermo 
Hybaid Multiblock System Software which was programmed for optimal annealing 
temperatures.  The resulting amplicons were then analyzed by using High Resolution 
Melting Analysis (HRMA) on the Light Scanner (see below).   
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DNA Amplicon Melting Curve Analysis 
 As a pre-screen to determine potential sequence mutations, analysis of melting 
curves from individual amplicons was performed using IdahoTech Light Scanner Hi-Res 
Melting technology and software.  Visibly altered melting curves for patient samples 
versus non-patient DNA indicated possible sequence variants or heteroduplexes that have 
different melting temperatures than the normal (wild type or WT) melting temperatures.  
A heteroduplex is made up of a mismatched, unstable pair of nucleotides (Figure-5).  If a 
dye is used to stain the DNA, its fluoresence decreases for heteroduplexes relative to 
homoduplexes since less is intercalated. 
 
 
 
Figure 5.  dsDNA Saturated with LCGreen 
Dye.  LG Green Dye enables fluorescence of 
dsDNA to be monitored during high resolution 
melting analysis of PCR products (Copied from 
Idaho Technology Inc., 2007) 
 
 
 
 
Both homoduplexes and heteroduplexes are amplified by PCR during the reaction 
(Figure-6).  The melting temperature of a heteroduplex’s dsDNA is lower than the 
melting temperature of a homoduplex, due to the base mismatches.  LC green dye was 
used to saturate dsDNA, and its fluorescence decreases for a heteroduplex.  This 
technique enabled the fluorescence of dsDNA to be monitored over a temperature range 
of 45° C to 98° C (Figure-7), and this high resolution melting analysis of PCR products 
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depicted the various melting curves and peaks which were individually analyzed for 
possible variants.  
 
 
Figure 6.  Theory For DNA Melting 
Analysis. During the reannealing step 
of PCR amplification, heteroduplexes 
and homoduplexes of both wildtype 
and mutant DNA become amplified.  
(Copied from Cellular and Molecular 
Biology - DNA Analysis, ncvs.org 
2005) 
 
 
 
 
 
 
 
 
Figure 7.  Example of the 
LightScanner Software Used for 
the Identification of Mutations and 
Polymorphisms.  Software detects 
the decrease in fluorescence 
associated with heteroduplex 
formation between mismatched 
nucleotides through fluorescence 
technology. (Mayo Clinic, 2007, 
Example of BX-1-2-3_Mre11-6) 
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DNA Sequence Analysis 
 PCR amplicons identified from the melting curve analyses as potentially 
containing mutations were subsequently verified by DNA sequencing.  The amplicons of 
potential variants were collected and transferred to a 96-well plate, on which the 
ExoSAP-IT protocol was performed to remove excess nucleotides and primers prior to 
robotic sequencing.  5 µL of molecular grade water and 2 µL of ExoSAP-IT were added 
to each reaction amplicon.  The samples were then placed on the PCR machine for PCR 
clean up.  The steps in the ExoSAP-IT protocol are as follows: 
1.  Incubate at 37° C for 20 minutes. 
2.  Incubate at 85° C for 20 minutes. 
3.  Incubate at 25° C forever. 
5 µL of the reaction from the original plate was then transferred to a new 96 well plate.  
Either the forward or reverse primer was then added to the corresponding amplicons and 
then placed on the PCR machine for a 5 minute 95° C denature period.  The plate was 
removed and the samples were transferred to a clear 96 well plate required for 
sequencing.  The plate was sent to the Mayo Sequencing Core to be processed. 
The ExoSAP-IT reagent, obtained from the USB Corporation, provided a one step 
PCR clean up that removes excess primers and dNTPs, in preparation for robotic 
sequencing.  The plates were then sent to the core sequencing center at the Mayo Clinic 
where sequence results were obtained.  These results were analyzed for specific 
mutations, including insertions, deletions, or frameshifts.  The samples with mutations 
were traced back to the initial DNA sample, so that the mutation could be identified along 
with the individual’s family pedigree.  Sequencing software used to detect these genetic 
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mutations included Applied Biosystems’ Sequence Scanner v1.0 and Gene Codes’ 
Sequencher 4.8.   NCBI’s dbSNP was accessed to compare mutations found within the 
novel susceptibility genes with those defined in the database as part of the HapMap 
project.  
 
Data Analysis 
 In order to determine if the identified mutations were disease specific mutations, a 
comprehensive analysis was conducted on the conserved domains among various species.  
These conserved domains have remained unchanged throughout evolution which 
suggests a vital role in gene functionality.  The genetic sequences obtained from the 
NCBI (National Center for Biotechnology Information) database along with the online 
bioinformatics tool ClustalW2 were used to align the different species’ MCPH1 protein 
sequences. A percentage of cross species conservation was calculated for each identified 
mutation. 
 
Data Collection 
 A detailed list of the genetic mutations identified within the MCPH1 gene was 
recorded to illustrate the family history, cross species conservation, type of mutation, 
amino acid change, nucleotide change, location of the mutation, minor allele frequency 
(MAF), observation frequency, and genotype of each sample analyzed.  
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RESULTS 
 
 
The purpose of this project was to identify mutations in novel BRCA pathway-
associated genes that could contribute to the onset of breast cancer.  The assumption was 
that the genetic loss of any gene related to this important DNA repair pathway could 
potentially lead to cancer, so breast cancer patients not showing the traditional BRCA1 or 
2 mutations might show mutations in BRACA-related genes.  Six BRCA-pathway genes 
were identified as candidates: Mre11, Rad50, NBS1, DSS1, BCCIP, and MCPH1.  
Mutations in these candidate genes were initially identified using High Resolution 
Melting Analysis (HRMA) (LightScanner analysis) of PCR amplicons of individual 
exons amplified from the DNA of non-BRCA1/BRCA2 breast cancer patient samples.  
Positives for MCPH1 were further analyzed by DNA sequencing.   
 
Primer Optimization on Human Placental DNA 
The project was initiated by designing PCR primers for each exon of the six 
candidate genes, then optimizing the PCR conditions for each primer pair using 
commercially obtained human DNA.  The optimum conditions determined for each 
primer pair are shown in Table-III below.  Figures 8-13 show example PCR gels for the 
optimization of the primers for MCPH1.  Tables IV and V show a typical 96-well format 
for the PCR reactions with a primer annealing temperature gradient established across the 
plate. 
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Table-III:  Optimized PCR Conditions for Each Candidate Gene Tested. 
Gene Candidate PCR Condition Changed From the General Protocol in Table-I 
MCPH1 
   Exon-1 
   Exon-2 
   Exon-3 
   Exon-4 
   Exon-5 
   Exon-6 
   Exon-7 
   Exon-8a 
   Exon-8b 
   Exon-8c 
   Exon-8d 
   Exon-8e 
   Exon-8f 
   Exon-8g 
   Exon-8h 
   Exon-9 
   Exon-10 
   Exon-11 
   Exon-12 
   Exon-13 
   Exon-14a 
   Exon-14b 
 
 
Strongest amplification at 66ºC 
Strongest amplification between 51-63ºC (55ºC) 
Strongest amplification between 52-63ºC (56ºC) 
Strongest amplification between 56-63ºC (59ºC) 
Strongest amplification between 56-66ºC (61ºC) 
Strongest amplification between 54-66ºC (59ºC) 
Strongest amplification between 54-66ºC (59ºC) 
Strongest amplification at 63ºC (63ºC) 
Strongest amplification between 52-66ºC (58ºC) 
Strongest amplification between 52-66ºC (56ºC) 
Strongest amplification between 59-69ºC (64ºC) 
Strongest amplification between 56-63ºC (59ºC) 
Strongest amplification between 54-66ºC (59ºC) 
Strongest amplification between 56-66ºC (61ºC) 
Strongest amplification between 60-63ºC (63ºC) 
Strongest amplification between 54-66ºC (63ºC) 
Strongest amplification between 51-63ºC (55ºC) 
Strongest amplification between 56-63ºC (63ºC) 
Strongest amplification between 56-63ºC (59ºC) 
Strongest amplification between 63-69ºC (66ºC) 
Strongest amplification between 59-66ºC (63ºC) 
Strongest amplification between 56-66ºC (61ºC) 
  
DSS1 
     Exon-1 
     Exon-2 
     Exon-3 
 
 
Strongest amplification between 63-69ºC (65 ºC) 
Strongest amplification at 63ºC (63 ºC) 
Strongest amplification between 59-66ºC (65 ºC) 
NBS1 
     Exon-1 
     Exon-2 
     Exon-3 
 
 
In progress. 
In progress. 
In progress. 
 
MRE11 
   Exon-1 
 
 
In progress. 
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   Exon-2 
   Exon-3 
   Exon-4 
   Exon-5 
   Exon-6 
   Exon-7 
   Exon-8 
   Exon-9 
   Exon-10 
   Exon-11 
   Exon-12 
   Exon-13 
   Exon-14 
   Exon-15 
   Exon-16 
   Exon-17 
   Exon-18 
   Exon-19 
   Exon-20 
 
Strongest amplification between 59-66ºC (63ºC) 
Strongest amplification between 54-59ºC (56ºC) 
Strongest amplification between 54-63ºC (58ºC) 
Strongest amplification between 54-63ºC (58ºC) 
Strongest amplification between 56-66ºC (61ºC) 
Strongest amplification between 50-52ºC (51ºC) 
Strongest amplification between 54-63ºC (58ºC) 
Failed, redesign primers 
Strongest amplification between 51-56ºC (53ºC) 
Strongest amplification between 54-63ºC (58ºC) 
Strongest amplification between 56-63ºC (59ºC) 
Strongest amplification between 59-66ºC (63ºC) 
Strongest amplification between 51-63ºC (57ºC) 
Strongest amplification between 56-59ºC (58ºC) 
Strongest amplification between 52-63ºC (56ºC) 
Strongest amplification between 54-59ºC (56ºC) 
Strongest amplification between 52-59ºC (56ºC) 
Strongest amplification between 52-59ºC (56ºC) 
Strongest amplification between 54-63ºC (59ºC) 
 
RAD50 
   Exon-1 
   Exon-2 
   Exon-3 
   Exon-4 
   Exon-5 
   Exon-6&7 
   Exon-8 
   Exon-9 
   Exon-10 
   Exon-11 
   Exon-12 
   Exon-13 
   Exon-14 
   Exon-15 
   Exon-16 
   Exon-17 
   Exon-18&19 
   Exon-20 
   Exon-21 
   Exon-22 
   Exon-23 
   Exon-24 
   Exon-25 
 
 
(Using working stock primers previously designed) 
Strongest amplification between 63-69ºC (66ºC) 
Failed, redesign primers 
Strongest amplification between 52-56ºC (54ºC at 50 cycles) 
Strongest amplification between 52-56ºC (54ºC) 
Failed, redesign primers 
Failed, redesign primers  
Failed, redesign primers; rerun - strongest 56-59ºC 
Failed, redesign primers; rerun - redesign 
Strongest amplification between 54-59ºC (56ºC) 
Strongest amplification between 51-59ºC (54ºC) 
Failed, redesign primers; rerun – strongest 54ºC 
Failed, redesign primers; rerun – strongest 54-56ºC 
Failed, redesign primers; rerun – strongest 52-56ºC 
Strongest amplification 52-56ºC; rerun- strongest 51-54ºC (52ºC) 
Strongest amplification between 51-56ºC (54ºC) 
Failed, redesign primers; rerun – strongest 63ºC 
Failed, redesign primers; rerun – strongest 56-63ºC 
Failed, redesign primers; rerun – strongest 54-59ºC 
Strongest amplification 56-59ºC (58ºC with 3 μL BX-1 DNA) 
Strongest amplification 56-59ºC (58ºC with 3 μL BX-1 DNA) 
Strongest amplification between 52-66ºC (56ºC) 
Strongest amplification between 52-59ºC (56ºC) 
Failed, redesign primers; rerun- 59-63ºC (weak); rerun - 56ºC 
(strong) (60ºC) 
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BCCIP 
   Exon-1 
   Exon-2 
   Exon-3 
   Exon-4 
   Exon-5 
   Exon-6 
 
 
 
Strongest amplification at 59ºC 
Strongest amplification between 51-59ºC 
Strongest amplification between 54-59ºC 
Strongest amplification between 56-63ºC 
Strongest amplification between 63-66ºC 
Strongest amplification between 59-66ºC 
 
 
 
 
Table-IV:  Diagram of the 96-well Coordinates and Annealing Temperature 
Gradient Used for Primer Optimization Tests. 
 
 
This table shows the 96-well format used for primer optimization.  A temperature 
gradient ranging from 50-72°C (blue color) was distributed across the 96-well plate (50-
70°C for 10 samples of each primer pair).   
Temperature Gradient (°C) 50 50.6 51.9 53.5 56 59.2 62.9 66 68.5 70.2 71.5 72
1 2 3 4 5 6 7 8 9 10 11 12
A  A1 A2 A3 A4 A5 A6 A7 A8 A9 A10 N/A N/A
B  B1 B2 B3 B4 B5 B6 B7 B8 B9 B10 N/A N/A
C  C1 C2 C3 C4 C5 C6 C7 C8 C9 C10 N/A N/A
D  D1 D2 D3 D4 D5 D6 D7 D8 D9 D10 N/A N/A
E  E1 E2 E3 E4 E5 E6 E7 E8 E9 E10 N/A N/A
F  F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 N/A N/A
G  G1 G2 G3 G4 G5 G6 G7 G8 G9 G10 N/A N/A
H  H1 H2 H3 H4 H5 H6 H7 H8 H9 H10 N/A N/A
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           Table-V:  Diagram of the Electrophoresis Lane Loadings. 
 
 The DNA marker and the PCR products were loaded into an agarose gel in 
the order listed in this table, and electrophoresis was performed.  The most 
optimum primer annealing temperatures were determined by analyzing the 
intensity of the amplicon bands present in the gel.  The marker was loaded 
into the bottom-most  and top-most wells.  Row A from the 96-well plate 
was loaded into every other well on the gel.  Row B was then loaded next 
to the A wells.  The same process was followed for rows C-H.    
 
 
 
 
A/B C/D E/F G/H 
marker marker marker marker 
blank blank blank blank 
blank blank blank blank 
blank blank blank blank 
blank blank blank blank 
B10 D10 F10 H10 
A10 C10 E10 G10 
B9 D9 F9 H9 
A9 C9 E9 G9 
B8 D8 F8 H8 
A8 C8 E8 G8 
B7 D7 F7 H7 
A7 C7 E7 G7 
B6 D6 F6 H6 
A6 C6 E6 G6 
B5 D5 F5 H5 
A5 C5 E5 G5 
B4 D4 F4 H4 
A4 C4 E4 G4 
B3 D3 F3 H3 
A3 C3 E3 G3 
B2 D2 F2 H2 
A2 C2 E2 G2 
B1 D1 F1 H1 
A1 C1 E1 G1 
marker marker marker marker 
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Figure 8.  Example of PCR Primer Optimization for  MCPH1 Using Human Placental 
DNA.  Figure shows a variety of PCR signals.  Primers 1 and 2 (first column), 3 and 4 (second 
column), and 5 and 6 (third column) show strong amplification, while primers 7 and 8a (right 
side) show weak amplification.   
 
 
Figure 9.  Example Assignment of Band Intensities.  This figure shows the same gel in Figure 
8 but with a list of temperatures tested and an assignment of band intensities. Each band was 
assigned an intensity value for that amplicon ranging from – to +++, with +++ being the 
strongest.   The temperature gradient ran from 50-70°C.  
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Figure 10.  PCR Band Intensities for MCPH1 Exons 8b-9.  Exons 8h and 9 
displayed very weak bands, indicating that the primers may need to be redesigned.  
After running the PCR gradient on those two exons a second time, stronger bands 
appeared on the gel that were later optimized. 
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Figure 11.  PCR Band Intensities for MCPH1 Exons 10-
14b.  The same method was used to determine the optimal 
primer annealing temperatures for exons 10-14b.  None of 
these primers failed. 
 
 
 42 
 
 
 
 
                          Figure 12.  PCR Band Intensities for BCCIP Exons 1-6. 
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Figure 13.  PCR Band Intensities for Mre11 Exons 10-17.  None of the primers for 
these exons failed in this gel. 
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PCR Amplification of Candidate Genes from Patient DNA 
Following primer pair optimization, the optimized PCR conditions were then 
applied to each of the six candidate genes from two hundred eighty-eight samples of 
germline DNA obtained from various collaborating centers in Europe and the U.S.  Each 
patient had an extensive family history of breast cancer, but none had a BRCA1 or 2 
mutation.   
We began by individually amplifying each exon in the six target genes.  Exons 
larger than 500 bp were split into multiple amplicons for analyses.  Table-VI shows a 
summary of the number of amplicons successfully obtained for the six candidate genes.  
All 14 exons were successfully obtained for MCPH1, all 3 exons for DSS1, 19 of 20 
exons for Mre11, 23 of 25 exons for Rad50, all 16-17 exons for NBS1, and all 7 exons 
for BCCIP were obtained. 
 
Table-VI:  Number of PCR Amplicons Obtained for Each Candidate Gene  
and Number of Amplicons Analyzed by HRMA. 
 
 
 
 
In this Table, column-1 shows the gene analyzed; column-2 shows the total known 
number of exons for that gene; column-3 shows the number of amplicons analyzed for 
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that gene, and column-4 shows the number of amplicons analyzed by High Resolution 
Melting Analysis (HRMA) for that gene. 
 
High Resolution Melting Analysis (HRMA) and Variant Sequencing 
 PCR amplicons for MCPH1, DSS1, Mre11, and Rad50 were analyzed by High 
Resolution Melting Analysis (HRMA) as a preliminary screen to identify potential 
sequence variants.  In this technique, heteroduplexes form during PCR between one DNA 
strand from the WT DNA and the other strand from a patient’s variant gene.  Mismatched 
duplexes intercalate less fluorescent dye than pure duplex DNA, so a decreasing 
fluorescent signal indicates the presence of potential sequence variants, which can 
subsequently be further analyzed by DNA sequencing.  HRMA Lightscanner Software 
was used to determine whether melting curves varied from the wild type curves to 
determine which of the 288 patient samples most likely contained mutations.  
 Table-VI (in the previous subsection) shows a summary of the number of 
amplicons analyzed by HRMA.  All 14 exons were analyzed for MCPH1, all 3 exons for 
DSS1, 10 of 20 exons for MRE11, 13 of 25 exons for RAD50, and none for NBS1 or 
BCCIP at this time.  LightScanner software was used to display the HRMA data.  Any 
curves that visually differed from the normal (wild type) curve indicated a potential 
sequence variant for that patient sample.  Potential variants were then analyzed by 
sequencing.    
 Of the four genes analyzed by PCR/HRMA to date, one MCPH1, was chosen for 
sequence analysis.  A preliminary analysis of DSS1 gene is shown in the Appendix, and 
is nearly completed.  DNAs were prepared for sequencing by using an ExoSAP IT 
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protocol to remove excess primers and nucleotides from the PCR reactions.  The final 
product samples were then placed on a sequencing plate and sent to the Mayo Clinic 
sequencing core to be sequenced.  The sequenced products were analyzed using 
Sequencher software, which assisted in identifying the location of a possible mutation 
within each amplicon.   
Figure 14 shows the HRMA LightScanner output for MCPH1 Exon-6 for Patient H1.  
The melting curve for exon-6 of patient H1 differs from the wild-type curve, indicating a 
possible sequence variant.  Figure 15 shows the Sequencher output for MCPH1 Exon-6 for 
patient E4 and H1, both showing sequence variants relative to WT DNA.   Figures 16-21 show 
examples of other sequence variants identified.
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Figure 14.  HRMA LightScanner Output for MCPH1 Exon-6 for Patient H1 (BR-32-515-
d05-3184).  The light colored double-peak curve for the patient DNA (lower right panel) differs 
from the darker colored single peak for WT DNA indicating a potential sequence variant. 
 
Figure 15.  Sequencher Output for MCPH1 Exon-6 for Two Patients E4 (BR-32-127-d00-
2063) and H1 (BR-32-515-d05-3184).  The upper sequence file for patient E4 (BR-32-127-d00-
2063) shows a homozygous S 171 R (TT) mutation relative to WT DNA (GG).  Note:  the WT 
sequence is not shown in this figure.  The lower sequence displays a heterozygous 581 G>T 
mutation (GT). 
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Figure 16.  HRMA LightScanner Output for MCPH1 Exon-7 for Patients K3 (FCP-119) 
and P5 (COH-2394-469-1).  This LightScanner output shows a double peak curve that is the 
wild type curve and a multiple peak curve that corresponds to the frameshift mutation (K3). 
 
 
Figure 17.  Sequencher Output for MCPH1 Exon-7 for Two Patients E22 (COH-1228-863-
1) and K3 (FCP-119).  This figure shows a frameshift mutation (Exon 7 c. 649 -7 ins T, IVS 6 -7 
ins T) in the second sequence file relative to the WT sequence (top sequence). 
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Figure 18.  HRMA LightScanner Output for MCPH1 Exon-8F for Patients J23 (FCP-10) 
and P5 (COH-2394-469-1).  This HRMA shows a pink curve wild type (P5) and an orange curve 
(J23) that corresponds to the frameshift mutation. 
 
 
Figure 19.  Sequencher Output for MCPH1 Exon-8F for Two Patients J23 (FCP-10) and 
A17.  The first sequence file is an example of a frameshift mutation.  In this sequence, there is an 
apparent shoulder on the peaks, which is an indication of a frameshift mutation (1464 Δ del A, fs 
(468) codon 466 stop 499).  In this specific example, a stop codon is formed at codon 499 in exon 
8f of the MCPH1 gene. 
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Figure 20.  LightScanner Output for MCPH1 Exon-8F for Patients P5 (COH-2394-469-1), 
G14 (COH-883-856-1), and J23 (FCP-10).  The pink curve (P5) is the wild type curve.  The 
orange and dark blue curves (G14 and J23) are heterozygous mutations.  The orange curve is also 
a frameshift mutation. 
 
 
 
 
Figure 21.  Sequencher Output for MCPH1 Exon-8F for Patients J23 (FCP-10), A17, and 
G14 (COH-883-856-1).  This is another example of a frameshift mutation (1496 C>T, F 476 F).  
The first sequence shows a mutation of C>T at position 85 in the frameshift/mutant sequence.  
The mutation is homozygous.  The second sequence displays the WT sequence, while the third 
sequence shows an individual that is heterozygous for the SNP. 
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  In order to determine how a particular amino acid would be altered by the 
nucleotide mutation, the location of the nucleotide within the correct reading frame of the 
coding sequence was identified.  Altered codons will change the resultant protein 
sequence, except for silent mutations where the protein is not altered or physically 
changed.  However, silent mutations may have some function in alternative splicing. 
 Once the locations of the amino acid changes had been recorded, the dbSNP 
NCBI database was accessed to determine the frequency of the SNPs previously 
identified in other population studies.  Since the 288 patient samples consisted of 
individuals from European countries, the Minor Allele Frequencies (MAFs) were 
calculated from the data available on European populations.  Novel SNPs, previously 
unidentified, were not recorded in the dbSNP database.  Frameshift mutations were also 
not available in the dbSNP database, because frameshifts alter the sequence of multiple 
nucleotides (rather than a single nucleotide).  The sequence data analysis summary for 
MCPH1 is shown in Table-VII below. 
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Table-VII:  Summary of the Sequence Analysis Mutation Screening for MCPH1. 
Coordinates exon nt change Genotype aa change dbSNP MAF Obs freq in X sequences 
(mutants/#samples 
sequenced) 
Cross species 
conservation 
I.Frameshifts/nonsense         
BX-1-2-3 J23 8f 1464 Δ del A   fs (468) codon 
466 stop 499 
  1 out of 23  
BX-1-2-3 J23 8f 1464 Δ del A; 
1496 C>T 
CT fs (468) codon 
466 stop 499; 
F 476 F 
rs2920676 0.0085 2 out of 23 2/8 del, 2/8 c, 4/8 nc 
BX-1-2-3 K3 7 c. 649 -7 ins 
T 
 IVS 6 -7 ins T   1 out of 16  
BX-1-2-3 C5 13-1 2375 ins C  (769) fs 772 
Stop 777 
  3 out of 48  
BX-1-2-3 E7 13-1 2375 ins C  (769) fs 772 
Stop 777 
  3 out of 48  
BX-1-2-3 K16 13-1 2375 ins C  (769) fs 772 
Stop 777 
  3 out of 48  
BX-1-2-3 J23 13-1 2375 Δ del C  (769) fs 
771Stop778 
  1 out of 48  
BX-1-2-3 G4 13-1 del 244  fs 818 Stop 
844 
  2 out of 48  
BX-1-2-3 D5 13-1 2283del238 
(ex.13 del) 
 fs 818 Stop 
844 
  2 out of 48  
II. Missense subst.         
BX-1-2-3 H1 3 237 C>A CA Q 57 K No  7 out of 24 100% c 
BX-1-2-3 M15 3 244 C>A CA T 59 N No  1 out of 24 100% c 
BX-1-2-3 O20 3 250 A>G AG D 61 G No  1 out of 24 7/8 c, 1/8 nc 
BX-1-2-3 I21 5 430 C>A CA P 121 Q No  14 out of 24 100% c 
BX-1-2-3 O21 6 581 G>T TT S 171 R rs2442513 0.25 30 out of 31 3/8 c, 3/8 sc, 2/8 nc 
BX-1-2-3 H1 6 581 G>T GT S 171 R rs2442513 0.25 1 out of 31 3/8 c, 3/8 sc, 2/8 nc 
BX-1-2-3 G14 8b 931 C>A CA P 288 H rs35590577 ??? 1 out of 15 1/8 del, 1/8 nc, 6/8 c 
BX-1-2-3 G14 8b 979 G>T GT R 304 I rs2083914 0.182 10 out of 15 5/8 c, 3/8 nc 
BX-1-2-3 L5 8b 1008 G>C CC D 314 H rs930557 0.207 5 out of 15 1/8 del, 5/8 c, 2/8 nc 
BX-1-2-3 O11 8b 1008 G>C GC D 314 H rs930557 0.207 9 out of 15 1/8 del, 5/8 c, 2/8 nc 
BX-1-2-3 I15 8d-1 1243 A>G GG D 392 G rs2515569 1 46 out of 46 2/8 del, 1/8 c, 5/8 nc 
(3G, 1R, 1Q) 
BX-1-2-3 M4 13-1 2350 C>T CT A 761 V rs1057090 0.481 23 out of 48 5/8 c (4V,1M), 2/8 nc, 
1/8 sc 
BX-1-2-3 G9 13-1 2350 C>T TT A 761 V rs1057090 0.481 9 out of 48 5/8 c (4V,1M), 2/8 nc, 
1/8 sc 
BX-1-2-3 M4 13-1 2476 C>A CA A 806 A rs2912016 0.43 21 out of 48 5/8 c, 2/8 sc, 1/8 nc 
BX-1-2-3 G9 13-1 2476 C>A AA A 806 A rs2912016 0.43 5 out of 48 5/8 c, 2/8 sc, 1/8 nc 
BX-1-2-3 H3 13-1 2287 G>A AA C 740 Y No  1 out of 48 7/8 c, 1/8 nc 
BX-1-2-3 B21 14 2540 C>T TT P 828 S No  6 out of 47 8/8 nc (4S, 2F, 1D, 1M 
whch is sc to S) 
BX-1-2-3 M8 14 2540 C>T TC P 828 S No  26 out of 47 8/8 nc (4S, 2F, 1D, 1M 
whch is sc to S) 
BX-1-2-3 D3 14 2562 C>A CA L 832 I No  47 out of 47? 6/8 c (5L, 1I), 2/8 sc 
III. Silent substitutions         
BX-1-2-3 A22 3 296 G>T TT V 76 V rs2305022 0.202 19 out of 24 100% c 
BX-1-2-3 D23 3 296 G>T GT V 76 V rs2305022 0.202 4 out of 24 100% c 
BX-1-2-3 I1 6 545 A>T TA S 159 S rs41313948 N/A 2 out of 31 100% c 
BX-1-2-3 I15 8d-1 1280 T>A TA A 404 A No  out of 46 2/8 del, 4/8 c, 2/8 sc 
BX-1-2-3 M4 8d-1 1280 T>A TT? A 404 A No  out of 46 2/8 del, 4/8 c, 2/8 sc 
BX-1-2-3 G14 8f 1496 C>T CT F 476 F rs2920676 0.0085 2 out of 23 2/8 del, 2/8 c, 4/8 nc 
BX-1-2-3 A21 8h 1850 G>A GA T 594 T rs2584 0.36 5 out of 8 2/8 del, 3/8 c, 3/8 nc 
BX-1-2-3 M20 8h 1850 G>A GA T 594 T rs2584 0.36 8 out of 21 2/8 del, 3/8 c, 3/8 nc 
BX-1-2-3 O20 8h 1850 G>A AA T 594 T rs2584 0.36 3 out of 21 2/8 del, 3/8 c, 3/8 nc 
BX-1-2-3 M4 13-1 2294 C>T CT S 742 S rs2912010 0.475 22 out of 48 2/8 c, 4/8 sc, 2/8 nc 
BX-1-2-3 G9 13-1 2294 C>T TT S 742 S rs2912010 0.475 9 out of 48 2/8 c, 4/8 sc, 2/8 nc 
BX-1-2-3 M4 13-1 2476 C>A CA A 806 A rs2912016 0.43 21 out of 48 5/8 c, 2/8 sc, 1/8 nc 
BX-1-2-3 G9 13-1 2476 C>A AA A 806 A rs2912016 0.43 5 out of 48 5/8 c, 2/8 sc, 1/8 nc 
BX-1-2-3 P7 13-1 2411 G>A GA L 781 L No  1 out of 48 100% c 
IV. Intronic variants         
BX-1-2-3 H3 I-9 2003+9 G>A AG ….. No  1 out of 47  
BX-1-2-3 F17 I-9 2003+69 
A>G 
AG ….. No  1 out of 47  
BX-1-2-3 M20 I-10F 2041+15 
T>A 
TA ….. No  1 out of 45  
BX-1-2-3 D3 I-14 2576+8 C>A CA ….. No  47 out of 47?  
 
Table-VII:  Summary of the Sequence Analysis Mutation Screening for Gene MCPH1. The columns 
in this table indicate the exon number for MCPH1, the observed nucleotide number change, the genotype 
for the mutation, the amino acid change designation, whether the mutation has been identified in the dbSNP 
database, the minor allele frequency (MAF), the observation frequency of the corresponding mutant, and 
the cross species conservation of the mutant amino acid.   
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 The project to date has found MCPH1 mutations in 29 of the 288 patient samples 
tested, 10 of which demonstrated more than one mutation.  Nine likely deleterious, 
frameshift/nonsense mutations, nineteen missense mutations, fourteen silent substitutions, 
and three intronic variants were found in the MCPH1 amplicons.  The mutations that are 
most likely disease-associated are the missense and frameshift mutations.  Frameshifts, 
missense mutations, and silent substitutions within amplicon 13-1 (exon 13) occurred 
most often within each of the three categories.  Six of the nine frameshifts, five of the 
nineteen missense mutations, and five of the fourteen silent substitutions occurred in 
amplicon 13-1 (exon13).   
 
 A cross species alignment was also performed for MCPH1 (Figure 22) for nine 
different species to determine the degree of conservation.  The more highly conserved the 
sequence domain, the more likely that domain is required for function, thus if a mutation 
occurs in a conserved domain it likely is deleterious.   The amino acids highlighted in red 
indicate the locations where mutations were observed in patient samples in the present 
study.  The cross species conservation for each of these mutations is also listed in the 
rightmost column of Table-VII.  We conclude from the amino acid alignments that 
several domains in MCPH1 are highly conserved and are likely required for function, and 
that 14 patient mutations were identified in these potential functional domains. 
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Figure 22.  Amino Acid Alignment for Nine Biological Species of MCPH1.  This analysis was 
performed to determine conserved domains to determine which patient mutations likely disrupt functional 
domains.  The alignment was performed using Clustal 2.0.8 software.  The species name is listed on the left 
side of the figure, and the corresponding amino acid sequence is given for each species. The letters in red 
indicate the amino acid mutations found in patient samples. 
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Pedigrees of Families with MCPH1 Mutations 
 
Figures-23, 24, 25, and 26 show the family pedigrees of patient samples found to 
have a serious frameshift mutation in the MCPH1 gene.  The males are indicated as 
squares, while the females are represented as circles. Patients with breast cancer are 
highlighted in black. The age of cancer diagnosis (in years) is indicated within the 
symbol and, in some cases, both ages are given for bilateral breast cancer. Other cancers 
noted were bladder (Bl), colon (Col), liver (Li), ovarian (Ov), pancreatic (Panc), prostate 
(Pr), sarcoma (Sarc), thyroid (Thy), and uterine (Ut).  The lines through symbols indicate 
deceased family members.   
 
  
 
 
 
 
Figure 23.  Pedigree of a 
Female Patient Identified with 
Breast Cancer at 41 Years of 
Age with an MCPH1 
Frameshift Mutation. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24.  Pedigree of a Female 
Patient Identified With Breast 
Cancer at 40 Years of Age With an 
MCPH1 Frameshift Mutation. 
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Figure 25.  Pedigree of female patient 
identified with bilateral breast cancer 
first at age 51 then again at 55 years with 
an MCPH1 Frameshift Mutation. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26.  Pedigree of A 
Female Patient Identified 
With Breast Cancer at Age 
51 with an MCPH1 
Frameshift Mutation. 
 
 
 
 
 
 
 
From these pedigrees it can be concluded that deleterious MCPH1 frameshift mutations 
occur in families with inherited early onset cancers.  In three of the four pedigrees shown, 
one or more of the patient’s family members died of early onset breast cancer.  Further 
studies may eventually show how widespread these MCPH1 mutations are.  Since these 
patients are from non-BRCA families, it can be inferred that frameshift mutations within 
the MCPH1 gene may have a significant effect on the onset of breast cancer.  
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DISCUSSION 
 
 
The data obtained from this project used a candidate gene screening approach to 
identify potential genetic changes in proteins previously shown to interact with BRCA1 
and/or BRCA2 in cellular pathways.  The coding sequences of 6 candidate genes 
MRE11, RAD50, MCPH1, NBS1, DSS1, and BCCIP were amplified by PCR from 288 
non-BRCA1/BRCA2 breast cancer patient DNA samples.  The amplicons were initially 
screened for mutations by High Resolution Melting Analysis (HRMA), and selected 
positives were further analyzed by sequence analysis.  Most of the data obtained so far is 
from gene MCPH1, which to date shows frameshift/nonsense mutations, missense 
mutations, silent substitutions, and intronic variants in 29 patients of the 288 patients 
analyzed so far.  Ten patient samples demonstrated more than one mutation in MCPH1.  
For gene DSS1 (see Appendix), all exons for that gene were obtained by PCR, analyzed 
by HRMA, and sequenced, but only exon 2 has been analyzed to date.  Within that 
amplicon, seven frameshift mutations and one SNP were found.  Thus in this study to 
date, putative breast cancer-associated mutations have been identified in candidate genes 
known to interact with BRCA1 and/or BRCA2 in the double-stranded DNA break repair 
pathway.  Importantly, the identified mutations include protein truncating and missense 
mutations in highly conserved domains.    
The data from this project support the findings of Friedenson (2005) who 
previously speculated that a breakdown in the DNA repair BRCA pathway may increase 
the risk for development of breast cancer, and who also proposed that inactivation of any 
component within the BRCA pathway may also increase the risks for ovarian cancers, 
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lymphomas, and leukemias (Friedenson 2007).  In addition, Chaplet et al. (2006) 
suggested that MCPH1 (also known as BRIT1) plays a role as a tumor suppressor.  
Depletion of BRIT1 (MCPH1) eliminates the DNA damage checkpoint and repair 
response, increasing the risk for the development and progression of cancer (Chaplet et 
al., 2006).  The majority of mutations that we found in MCPH1 were missense mutations 
in conserved domains, so these could disrupt function.  In addition, the nine frameshift 
mutations observed in MCPH1 are probably serious mutations that most likely could 
cause disease in those patients.  So perhaps a proportion of the cancer observed in non-
BRCA1/BRCA2 families can be explained by these observed mutations in the MCPH1 
gene.   
 Problems encountered while working on this project included difficulty 
amplifying certain exons by PCR, which led to a redesign and reoptimization of primers 
in many instances.  In addition, the HRMA assay used as a pre-screening method to 
identify potential mutations was not very efficient or consistent at detecting the mutations 
later identified by sequencing.  It was also somewhat difficult to manage the large 
amounts of data generated in this project, especially when analyzing so many patient 
samples.   
 In the future, database software programs may be useful for organizing the data.  
In addition, MCPH1 mutation segregation studies and penetrance estimation studies 
could be done to determine disease-risk.  Additional studies could also be completed on 
other candidate genes to continue to identify genes that contribute to an unexplained 
familial risk for breast cancer. 
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Appendix 
 
 
Sequence Analysis of DSS1 
 For gene DSS1, all exons for that gene were obtained by PCR, analyzed by 
HRMA, and sequenced, but only the data for exon-2 has been analyzed to date.  Within 
exon-2 (Table-VIII, upper half), seven frameshift mutations and one SNP were found in 8 
patient samples.  
 
Table-VIII.  Sequence Analysis of DSS1. 
DSS1 Mutation Screening on BX-1-2-3 
coord Seq_folder
sequencher 
project exon seq file nt nt change
genoty
pe aa change dbSNP?
Obs freq 
in X 
sequences 
(mutants/#
samples 
sequence
d)
BX-1-2-3 M20 111307_be_2 2 2 fs until nt 90 FRAMESHIFT FRAMESHIFT  2 out of 11
BX-1-2-3 I4 111307_be_2 2 2 fs until nt 90 FRAMESHIFT FRAMESHIFT  2 out of 11
BX-1-2-3 C2 111307_be_2 2 2 fs until nt 156 FRAMESHIFT FRAMESHIFT 1 out of 11
BX-1-2-3 G4 111307_be_2 2 2 fs until nt 160 FRAMESHIFT FRAMESHIFT 1 out of 11
BX-1-2-3 K16 111307_be_2 2 2 fs until nt 158 FRAMESHIFT FRAMESHIFT 1 out of 11
BX-1-2-3 J5 111307_be_2 2 2 fs until nt 114 FRAMESHIFT FRAMESHIFT 1 out of 11
BX-1-2-3 L5 111307_be_2 2 2 fs until nt 104 FRAMESHIFT FRAMESHIFT 1 out of 11
BX-1-2-3 I4 111307_be_2 2 2 232 284 C>T CT F 52 F no 1 out of 11  
This table contains the sequence analysis performed to date for DSS1.  The data for exon-2 are 
shown in this table.   Identification of the variants is currently in progress.  Frameshift mutations 
have been positively identified within exon-2 for seven patient samples, and one patient sample 
displayed a SNP within the same amplicon. 
 
 The DSS1 data obtained to date support Li et al.’s (2006) suggestion that DSS1 
depletion causes hypersensitivity to DNA damage, similar to that shown with BRCA2 
mutations.  These authors found DSS1 to be essential to the stability of the BRCA2 
protein in mammalian cells, and suggested that its deletion, suppression, or mutation, 
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would promote human breast and ovarian cancer, as well as sporadic and familiar breast 
cancer where BRCA1 and BRCA2 mutations are absent (Li et al. 2006).    
 
 
 
